New hope for liver cancer patients with damaged livers?

NCT ID NCT05622071

Completed Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 22, 2026 · Updated 28 times

Summary

This study tested a drug called tislelizumab in 50 people with advanced liver cancer who also have moderate liver damage (Child-Pugh B). The goal was to see if the drug could shrink tumors. Tislelizumab works by helping the immune system attack cancer cells. The study took place in France and included patients who may or may not have had prior treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA BY BCLC STAGE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

CHRU Strasbourg

Strasbourg, France
CHU Angers

Angers, France
CHU Beaujon

Clichy, France
CHU La Croix Rousse

Lyon, France
CHU Saint Eloi

Montpellier, France
Centre Eugene Marquis

Rennes, France
Hôpital Avicenne

Bobigny, France
Hôpital Michallon

Grenoble, France
Hôpital Saint Joseph

Marseille, France
Institut Paoli Calmette

Marseille, France

Conditions

Explore the condition pages connected to this study.

HEPATOCELLULAR CARCINOMA BY BCLC STAGE